$11.92
0.93%
Nasdaq, Aug 22, 10:09 pm CET
ISIN
BMG762791017
Symbol
ROIV

Roivant Sciences Stock price

$11.92
+0.42 3.65% 1M
+1.40 13.31% 6M
+0.09 0.76% YTD
+0.24 2.05% 1Y
+8.24 223.91% 3Y
+2.00 20.16% 5Y
+2.00 20.16% 10Y
+2.00 20.16% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.11 0.93%
ISIN
BMG762791017
Symbol
ROIV
Industry

Key metrics

Basic
Market capitalization
$8.1b
Enterprise Value
$3.3b
Net debt
positive
Cash
$4.9b
Shares outstanding
695.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
280.2 | 316.2
EV/Sales
112.0 | 126.3
EV/FCF
negative
P/B
1.7
Financial Health
Equity Ratio
86.2%
Return on Equity
-3.7%
ROCE
-21.1%
ROIC
-227.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$29.1m | $25.7m
EBITDA
$-1.1b | $-1.3b
EBIT
$-1.1b | $-1.2b
Net Income
$-172.0m | $-985.5m
Free Cash Flow
$-844.1m
Growth (TTM | estimate)
Revenue
-76.7% | -11.4%
EBITDA
-1.4% | -17.2%
EBIT
-0.7% | -6.2%
Net Income
-104.0% | -473.0%
Free Cash Flow
-10.1%
Margin (TTM | estimate)
Gross
96.9%
EBITDA
-3,784.8% | -5,006.8%
EBIT
-3,833.3%
Net
-592.0% | -3,827.7%
Free Cash Flow
-2,905.2%
More
EPS
$-0.2
FCF per Share
$-1.2
Short interest
7.5%
Employees
750
Rev per Employee
$40.0k
Show more

Is Roivant Sciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Roivant Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Roivant Sciences forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a Roivant Sciences forecast:

Buy
88%
Hold
12%

Financial data from Roivant Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
29 29
77% 77%
100%
- Direct Costs 0.91 0.91
94% 94%
3%
28 28
74% 74%
97%
- Selling and Administrative Expenses 591 591
14% 14%
2,036%
- Research and Development Expense 550 550
4% 4%
1,895%
-1,100 -1,100
1% 1%
-3,785%
- Depreciation and Amortization 14 14
36% 36%
48%
EBIT (Operating Income) EBIT -1,114 -1,114
1% 1%
-3,834%
Net Profit -172 -172
104% 104%
-592%

In millions USD.

Don't miss a Thing! We will send you all news about Roivant Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roivant Sciences Stock News

Positive
Seeking Alpha
10 days ago
Roivant Sciences Ltd.'s Vant model gives it risk-isolated development, monetization flexibility, and diversified optionality. ROIV's main value drivers are Immunovant, Priovant, Pulmovant, and Genevant. All of these Vants are progressing well in 2025. However, its main near-term catalyst is Brepocitinib's Phase 3 in dermatomyositis. This could become the first approved therapy for this condition.
Positive
The Motley Fool
12 days ago
Monday's hangover turned into Tuesday's party for healthcare stock Roivant Sciences (ROIV 3.58%). On the back of a modest but meaningful analyst price target hike, investors bid the stock up by nearly 4% following a post-earnings slide the day before.
Negative
The Motley Fool
14 days ago
Commercial-stage biotech Roivant Sciences (ROIV -2.79%) started the trading week with an earnings release. In retrospect, that might not have been the wisest move.
More Roivant Sciences News

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Head office Bermuda
CEO Matthew Gline
Employees 750
Founded 2014
Website roivant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today